APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vasodilators for Heart Disease

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Vasodilators for Heart Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025194 pages

Choose your research edition.

Industry ResearchVasodilators for Heart Disease Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Vasodilators for Heart Disease Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Vasodilators for Heart Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vasodilators for Heart Disease Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Vasodilators for Heart Disease Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Vasodilators for Heart Disease market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Vasodilators for Heart Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vasodilators for Heart Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vasodilators for Heart Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Vasodilators for Heart Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vasodilators for Heart Disease include Chongqing Yaoyou Pharmaceutical Co., Ltd., Southwest Pharmaceutical Co., Ltd., Shanghai Hefeng Pharmaceutical Co., Ltd., Shanghai Aifa Pharmaceutical Co., Ltd., Shanxi Kangbao Biological Products Co., Ltd., Shandong New Era Pharmaceutical Co., Ltd., Shandong Fangming Pharmaceutical Group Co., Ltd., Sancai Shiqi Pharmaceutical Co., Ltd. and Lunan Beite Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

On the production side, the report examines Vasodilators for Heart Disease output, growth rates, and market shares by manufacturer and by region (at regional and country level) for 2021-2026, with forecasts through 2032.

On the consumption side, the report analyzes sales of Vasodilators for Heart Disease by region (regional and country level), company, type, and application for 2021-2026 and provides forecasts through 2032.

The report provides an overview of the global Vasodilators for Heart Disease market in terms of capacity, output, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vasodilators for Heart Disease and consumption patterns in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vasodilators for Heart Disease sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by type and application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vasodilators for Heart Disease market size, projected growth trends, production technologies, key applications, and end-use industries.

Vasodilators for Heart Disease Segment by Company

Chongqing Yaoyou Pharmaceutical Co., Ltd.

Southwest Pharmaceutical Co., Ltd.

Shanghai Hefeng Pharmaceutical Co., Ltd.

Shanghai Aifa Pharmaceutical Co., Ltd.

Shanxi Kangbao Biological Products Co., Ltd.

Shandong New Era Pharmaceutical Co., Ltd.

Shandong Fangming Pharmaceutical Group Co., Ltd.

Sancai Shiqi Pharmaceutical Co., Ltd.

Lunan Beite Pharmaceutical Co., Ltd.

Jiangxi Haiersi Pharmaceutical Co., Ltd.

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Jiangsu Shenlong Pharmaceutical Co., Ltd.

Jiangsu Jiuxu Pharmaceutical Co., Ltd.

Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd.

Hulunbeier Songlu Pharmaceutical Co., Ltd.

Henan Runhong Pharmaceutical Co., Ltd.

Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.

Chenxin Pharmaceutical Co., Ltd.

Beijing Yimin Pharmaceutical Co., Ltd.

Beijing Hengsheng Pharmaceutical Co., Ltd.

Anhui Fengyuan Pharmaceutical Co., Ltd.

TORRENT PHARMA INC.

Sanofi

Pfizer

Matins Pharma

Copperhead Chemical Company

Axplora

Aditya Chemicals

Vasodilators for Heart Disease Segment by Type

Isosorbide Mononitrate

Nicorandil

Nitroglycerin

Isosorbide Dinitrate

Vasodilators for Heart Disease Segment by Application

Clinic

Hospital

Other

Vasodilators for Heart Disease Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vasodilators for Heart Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vasodilators for Heart Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vasodilators for Heart Disease.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vasodilators for Heart Disease market, including product definition, global market growth prospects, production value, capacity, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vasodilators for Heart Disease industry.

Chapter 3: Detailed analysis of Vasodilators for Heart Disease market competition landscape. Including Vasodilators for Heart Disease manufacturers' output value, output and average price from 2021 to 2026, as well as competition analysis indicators such as origin, product type, application, merger and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 7: Production/Production Value of Vasodilators for Heart Disease by region. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 8: Consumption of Vasodilators for Heart Disease in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Vasodilators for Heart Disease Industry Trends Table 2. Vasodilators for Heart Disease Industry Drivers Table 3. Vasodilators for Heart Disease Industry Opportunities and Challenges Table 4. Vasodilators for Heart Disease Industry Restraints Table 5. Global Vasodilators for Heart Disease Production Value by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Vasodilators for Heart Disease Production Value Share by Manufacturers (2021-2026) Table 7. Global Vasodilators for Heart Disease Production by Manufacturers (Units) & (2021-2026) Table 8. Global Vasodilators for Heart Disease Production Market Share by Manufacturers Table 9. Global Vasodilators for Heart Disease Average Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Vasodilators for Heart Disease Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Vasodilators for Heart Disease Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Vasodilators for Heart Disease Manufacturers, Product Type & Application Table 13. Global Vasodilators for Heart Disease Manufacturers Established Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Vasodilators for Heart Disease by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Production Value of 2025) Table 16. Major Manufacturers of Isosorbide Mononitrate Table 17. Major Manufacturers of Nicorandil Table 18. Major Manufacturers of Nitroglycerin Table 19. Major Manufacturers of Isosorbide Dinitrate Table 20. Global Vasodilators for Heart Disease Production by Type 2021 VS 2025 VS 2032 (Units) Table 21. Global Vasodilators for Heart Disease Production by Type (2021-2026) & (Units) Table 22. Global Vasodilators for Heart Disease Production by Type (2027-2032) & (Units) Table 23. Global Vasodilators for Heart Disease Production Market Share by Type (2021-2026) Table 24. Global Vasodilators for Heart Disease Production Market Share by Type (2027-2032) Table 25. Global Vasodilators for Heart Disease Production Value by Type 2021 VS 2025 VS 2032 (Units) Table 26. Global Vasodilators for Heart Disease Production Value by Type (2021-2026) & (Units) Table 27. Global Vasodilators for Heart Disease Production Value by Type (2027-2032) & (Units) Table 28. Global Vasodilators for Heart Disease Production Value Market Share by Type (2021-2026) Table 29. Global Vasodilators for Heart Disease Production Value Market Share by Type (2027-2032) Table 30. Major Manufacturers of Clinic Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Other Table 33. Global Vasodilators for Heart Disease Production by Application 2021 VS 2025 VS 2032 (Units) Table 34. Global Vasodilators for Heart Disease Production by Application (2021-2026) & (Units) Table 35. Global Vasodilators for Heart Disease Production by Application (2027-2032) & (Units) Table 36. Global Vasodilators for Heart Disease Production Market Share by Application (2021-2026) Table 37. Global Vasodilators for Heart Disease Production Market Share by Application (2027-2032) Table 38. Global Vasodilators for Heart Disease Production Value by Application 2021 VS 2025 VS 2032 (Units) Table 39. Global Vasodilators for Heart Disease Production Value by Application (2021-2026) & (Units) Table 40. Global Vasodilators for Heart Disease Production Value by Application (2027-2032) & (Units) Table 41. Global Vasodilators for Heart Disease Production Value Market Share by Application (2021-2026) Table 42. Global Vasodilators for Heart Disease Production Value Market Share by Application (2027-2032) Table 43. Chongqing Yaoyou Pharmaceutical Co., Ltd. Company Information Table 44. Chongqing Yaoyou Pharmaceutical Co., Ltd. Business Overview Table 45. Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 47. Chongqing Yaoyou Pharmaceutical Co., Ltd. Recent Development Table 48. Southwest Pharmaceutical Co., Ltd. Company Information Table 49. Southwest Pharmaceutical Co., Ltd. Business Overview Table 50. Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 52. Southwest Pharmaceutical Co., Ltd. Recent Development Table 53. Shanghai Hefeng Pharmaceutical Co., Ltd. Company Information Table 54. Shanghai Hefeng Pharmaceutical Co., Ltd. Business Overview Table 55. Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 57. Shanghai Hefeng Pharmaceutical Co., Ltd. Recent Development Table 58. Shanghai Aifa Pharmaceutical Co., Ltd. Company Information Table 59. Shanghai Aifa Pharmaceutical Co., Ltd. Business Overview Table 60. Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 62. Shanghai Aifa Pharmaceutical Co., Ltd. Recent Development Table 63. Shanxi Kangbao Biological Products Co., Ltd. Company Information Table 64. Shanxi Kangbao Biological Products Co., Ltd. Business Overview Table 65. Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 67. Shanxi Kangbao Biological Products Co., Ltd. Recent Development Table 68. Shandong New Era Pharmaceutical Co., Ltd. Company Information Table 69. Shandong New Era Pharmaceutical Co., Ltd. Business Overview Table 70. Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 72. Shandong New Era Pharmaceutical Co., Ltd. Recent Development Table 73. Shandong Fangming Pharmaceutical Group Co., Ltd. Company Information Table 74. Shandong Fangming Pharmaceutical Group Co., Ltd. Business Overview Table 75. Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 77. Shandong Fangming Pharmaceutical Group Co., Ltd. Recent Development Table 78. Sancai Shiqi Pharmaceutical Co., Ltd. Company Information Table 79. Sancai Shiqi Pharmaceutical Co., Ltd. Business Overview Table 80. Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 82. Sancai Shiqi Pharmaceutical Co., Ltd. Recent Development Table 83. Lunan Beite Pharmaceutical Co., Ltd. Company Information Table 84. Lunan Beite Pharmaceutical Co., Ltd. Business Overview Table 85. Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 87. Lunan Beite Pharmaceutical Co., Ltd. Recent Development Table 88. Jiangxi Haiersi Pharmaceutical Co., Ltd. Company Information Table 89. Jiangxi Haiersi Pharmaceutical Co., Ltd. Business Overview Table 90. Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 92. Jiangxi Haiersi Pharmaceutical Co., Ltd. Recent Development Table 93. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information Table 94. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview Table 95. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 97. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Development Table 98. Jiangsu Shenlong Pharmaceutical Co., Ltd. Company Information Table 99. Jiangsu Shenlong Pharmaceutical Co., Ltd. Business Overview Table 100. Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 102. Jiangsu Shenlong Pharmaceutical Co., Ltd. Recent Development Table 103. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Company Information Table 104. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Business Overview Table 105. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 107. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Recent Development Table 108. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Company Information Table 109. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Business Overview Table 110. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 112. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Recent Development Table 113. Hulunbeier Songlu Pharmaceutical Co., Ltd. Company Information Table 114. Hulunbeier Songlu Pharmaceutical Co., Ltd. Business Overview Table 115. Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 117. Hulunbeier Songlu Pharmaceutical Co., Ltd. Recent Development Table 118. Henan Runhong Pharmaceutical Co., Ltd. Company Information Table 119. Henan Runhong Pharmaceutical Co., Ltd. Business Overview Table 120. Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 122. Henan Runhong Pharmaceutical Co., Ltd. Recent Development Table 123. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Company Information Table 124. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Business Overview Table 125. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 127. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Recent Development Table 128. Chenxin Pharmaceutical Co., Ltd. Company Information Table 129. Chenxin Pharmaceutical Co., Ltd. Business Overview Table 130. Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 132. Chenxin Pharmaceutical Co., Ltd. Recent Development Table 133. Beijing Yimin Pharmaceutical Co., Ltd. Company Information Table 134. Beijing Yimin Pharmaceutical Co., Ltd. Business Overview Table 135. Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 137. Beijing Yimin Pharmaceutical Co., Ltd. Recent Development Table 138. Beijing Hengsheng Pharmaceutical Co., Ltd. Company Information Table 139. Beijing Hengsheng Pharmaceutical Co., Ltd. Business Overview Table 140. Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 142. Beijing Hengsheng Pharmaceutical Co., Ltd. Recent Development Table 143. Anhui Fengyuan Pharmaceutical Co., Ltd. Company Information Table 144. Anhui Fengyuan Pharmaceutical Co., Ltd. Business Overview Table 145. Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 147. Anhui Fengyuan Pharmaceutical Co., Ltd. Recent Development Table 148. TORRENT PHARMA INC. Company Information Table 149. TORRENT PHARMA INC. Business Overview Table 150. TORRENT PHARMA INC. Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. TORRENT PHARMA INC. Vasodilators for Heart Disease Product Portfolio Table 152. TORRENT PHARMA INC. Recent Development Table 153. Sanofi Company Information Table 154. Sanofi Business Overview Table 155. Sanofi Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Sanofi Vasodilators for Heart Disease Product Portfolio Table 157. Sanofi Recent Development Table 158. Pfizer Company Information Table 159. Pfizer Business Overview Table 160. Pfizer Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Pfizer Vasodilators for Heart Disease Product Portfolio Table 162. Pfizer Recent Development Table 163. Matins Pharma Company Information Table 164. Matins Pharma Business Overview Table 165. Matins Pharma Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. Matins Pharma Vasodilators for Heart Disease Product Portfolio Table 167. Matins Pharma Recent Development Table 168. Copperhead Chemical Company Company Information Table 169. Copperhead Chemical Company Business Overview Table 170. Copperhead Chemical Company Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 171. Copperhead Chemical Company Vasodilators for Heart Disease Product Portfolio Table 172. Copperhead Chemical Company Recent Development Table 173. Axplora Company Information Table 174. Axplora Business Overview Table 175. Axplora Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 176. Axplora Vasodilators for Heart Disease Product Portfolio Table 177. Axplora Recent Development Table 178. Aditya Chemicals Company Information Table 179. Aditya Chemicals Business Overview Table 180. Aditya Chemicals Vasodilators for Heart Disease Production (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 181. Aditya Chemicals Vasodilators for Heart Disease Product Portfolio Table 182. Aditya Chemicals Recent Development Table 183. Global Vasodilators for Heart Disease Production by Region: 2021 VS 2025 VS 2032 (Units) Table 184. Global Vasodilators for Heart Disease Production by Region (2021-2026) & (Units) Table 185. Global Vasodilators for Heart Disease Production Market Share by Region (2021-2026) Table 186. Global Vasodilators for Heart Disease Production Forecast by Region (2027-2032) & (Units) Table 187. Global Vasodilators for Heart Disease Production Market Share Forecast by Region (2027-2032) Table 188. Global Vasodilators for Heart Disease Production Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 189. Global Vasodilators for Heart Disease Production Value by Region (2021-2026) & (US$ Million) Table 190. Global Vasodilators for Heart Disease Production Value Share by Region (2021-2026) Table 191. Global Vasodilators for Heart Disease Production Value by Region (2027-2032) & (US$ Million) Table 192. Global Vasodilators for Heart Disease Production Value Share by Region: (2027-2032) & (US$ Million) Table 193. Global Vasodilators for Heart Disease Market Average Price (US$/Unit) by Region (2021-2026) Table 194. Global Vasodilators for Heart Disease Market Average Price (US$/Unit) by Region (2027-2032) Table 195. Global Vasodilators for Heart Disease Consumption by Region: 2021 VS 2025 VS 2032 (Units) Table 196. Global Vasodilators for Heart Disease Consumption by Region (2021-2026) & (Units) Table 197. Global Vasodilators for Heart Disease Consumption Market Share by Region (2021-2026) Table 198. Global Vasodilators for Heart Disease Consumption Forecasted by Region (2027-2032) & (Units) Table 199. Global Vasodilators for Heart Disease Consumption Forecasted Market Share by Region (2027-2032) Table 200. North America Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 201. North America Vasodilators for Heart Disease Consumption by Country (2021-2026) & (Units) Table 202. North America Vasodilators for Heart Disease Consumption by Country (2027-2032) & (Units) Table 203. Europe Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 204. Europe Vasodilators for Heart Disease Consumption by Country (2021-2026) & (Units) Table 205. Europe Vasodilators for Heart Disease Consumption by Country (2027-2032) & (Units) Table 206. Asia Pacific Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 207. Asia Pacific Vasodilators for Heart Disease Consumption by Country (2021-2026) & (Units) Table 208. Asia Pacific Vasodilators for Heart Disease Consumption by Country (2027-2032) & (Units) Table 209. South America Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 210. South America Vasodilators for Heart Disease Consumption by Country (2021-2026) & (Units) Table 211. South America Vasodilators for Heart Disease Consumption by Country (2027-2032) & (Units) Table 212. Middle East & Africa Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 213. Middle East & Africa Vasodilators for Heart Disease Consumption by Country (2021-2026) & (Units) Table 214. Middle East & Africa Vasodilators for Heart Disease Consumption by Country (2027-2032) & (Units) Table 215. Key Raw Materials Table 216. Raw Materials Key Suppliers Table 217. Vasodilators for Heart Disease Distributors List Table 218. Vasodilators for Heart Disease Customers List Table 219. Research Programs/Design for This Report Table 220. Authors List of This Report Table 221. Secondary Sources Table 222. Primary Sources List of Figures Figure 1. Vasodilators for Heart Disease Product Image Figure 2. Global Vasodilators for Heart Disease Production Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vasodilators for Heart Disease Production Value (2021-2032) & (US$ Million) Figure 4. Global Vasodilators for Heart Disease Production Capacity (2021-2032) & (Units) Figure 5. Global Vasodilators for Heart Disease Production (2021-2032) & (Units) Figure 6. Global Vasodilators for Heart Disease Average Price (US$/Unit) & (2021-2032) Figure 7. Global Top 5 and 10 Vasodilators for Heart Disease Players Market Share by Production Value in 2025 Figure 8. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Isosorbide Mononitrate Image Figure 10. Nicorandil Image Figure 11. Nitroglycerin Image Figure 12. Isosorbide Dinitrate Image Figure 13. Global Vasodilators for Heart Disease Production by Type (2021 VS 2025 VS 2032) & (Units) Figure 14. Global Vasodilators for Heart Disease Production Market Share 2021 VS 2025 VS 2032 Figure 15. Global Vasodilators for Heart Disease Production Market Share by Type (2021-2032) Figure 16. Global Vasodilators for Heart Disease Production Value by Type (2021 VS 2025 VS 2032) & (Units) Figure 17. Global Vasodilators for Heart Disease Production Value Share 2021 VS 2025 VS 2032 Figure 18. Global Vasodilators for Heart Disease Production Value Share by Type (2021-2032) Figure 19. Clinic Image Figure 20. Hospital Image Figure 21. Other Image Figure 22. Global Vasodilators for Heart Disease Production by Application (2021 VS 2025 VS 2032) & (Units) Figure 23. Global Vasodilators for Heart Disease Production Market Share 2021 VS 2025 VS 2032 Figure 24. Global Vasodilators for Heart Disease Production Market Share by Application (2021-2032) Figure 25. Global Vasodilators for Heart Disease Production Value by Application (2021 VS 2025 VS 2032) & (Units) Figure 26. Global Vasodilators for Heart Disease Production Value Share 2021 VS 2025 VS 2032 Figure 27. Global Vasodilators for Heart Disease Production Value Share by Application (2021-2032) Figure 28. Global Vasodilators for Heart Disease Production by Region: 2021 VS 2025 VS 2032 (Units) Figure 29. Global Vasodilators for Heart Disease Production Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Vasodilators for Heart Disease Production Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Vasodilators for Heart Disease Production Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Vasodilators for Heart Disease Production Value (2021-2032) & (US$ Million) Figure 33. Europe Vasodilators for Heart Disease Production Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Vasodilators for Heart Disease Production Value (2021-2032) & (US$ Million) Figure 35. South America Vasodilators for Heart Disease Production Value (2021-2032) & (US$ Million) Figure 36. Middle East & Africa Vasodilators for Heart Disease Production Value (2021-2032) & (US$ Million) Figure 37. North America Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 38. North America Vasodilators for Heart Disease Consumption Market Share by Country (2021-2032) Figure 39. U.S. Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 40. Canada Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 41. Mexico Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 42. Europe Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 43. Europe Vasodilators for Heart Disease Consumption Market Share by Country (2021-2032) Figure 44. Germany Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 45. France Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 46. U.K. Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 47. Italy Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 48. Netherlands Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 49. Asia Pacific Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 50. Asia Pacific Vasodilators for Heart Disease Consumption Market Share by Country (2021-2032) Figure 51. China Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 52. Japan Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 53. South Korea Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 54. Southeast Asia Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 55. India Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 56. Australia Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 57. South America Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 58. South America Vasodilators for Heart Disease Consumption Market Share by Country (2021-2032) Figure 59. Brazil Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 60. Argentina Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 61. Chile Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 62. Colombia Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 63. Middle East & Africa Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 64. Middle East & Africa Vasodilators for Heart Disease Consumption Market Share by Country (2021-2032) Figure 65. Egypt Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 66. South Africa Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 67. Israel Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 68. Türkiye Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 69. GCC Countries Vasodilators for Heart Disease Consumption and Growth Rate (2021-2032) & (Units) Figure 70. Vasodilators for Heart Disease Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Vasodilators for Heart Disease Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Isosorbide Mononitrate
  • Nicorandil
  • Nitroglycerin
  • Isosorbide Dinitrate
Applications
  • Clinic
  • Hospital
  • Other
Companies covered
  • Chongqing Yaoyou Pharmaceutical Co., Ltd.
  • Southwest Pharmaceutical Co., Ltd.
  • Shanghai Hefeng Pharmaceutical Co., Ltd.
  • Shanghai Aifa Pharmaceutical Co., Ltd.
  • Shanxi Kangbao Biological Products Co., Ltd.
  • Shandong New Era Pharmaceutical Co., Ltd.
  • Shandong Fangming Pharmaceutical Group Co., Ltd.
  • Sancai Shiqi Pharmaceutical Co., Ltd.
  • Lunan Beite Pharmaceutical Co., Ltd.
  • Jiangxi Haiersi Pharmaceutical Co., Ltd.
  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  • Jiangsu Shenlong Pharmaceutical Co., Ltd.
  • Jiangsu Jiuxu Pharmaceutical Co., Ltd.
  • Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd.
  • Hulunbeier Songlu Pharmaceutical Co., Ltd.
  • Henan Runhong Pharmaceutical Co., Ltd.
  • Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.
  • Chenxin Pharmaceutical Co., Ltd.
  • Beijing Yimin Pharmaceutical Co., Ltd.
  • Beijing Hengsheng Pharmaceutical Co., Ltd.
  • Anhui Fengyuan Pharmaceutical Co., Ltd.
  • TORRENT PHARMA INC.
  • Sanofi
  • Pfizer
  • Matins Pharma
  • Copperhead Chemical Company
  • Axplora
  • Aditya Chemicals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vasodilators for Heart Disease Production Value Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Vasodilators for Heart Disease Production Capacity Estimates and Forecasts (2021-2032)
  5. 1.2.3 Global Vasodilators for Heart Disease Production Estimates and Forecasts (2021-2032)
  6. 1.2.4 Global Vasodilators for Heart Disease Market Average Price (2021-2032)
  7. 1.3 Assumptions and Limitations
  8. 1.4 Study Goals and Objectives
2 Global Vasodilators for Heart Disease Market Dynamics
  1. 2.1 Vasodilators for Heart Disease Industry Trends
  2. 2.2 Vasodilators for Heart Disease Industry Drivers
  3. 2.3 Vasodilators for Heart Disease Industry Opportunities and Challenges
  4. 2.4 Vasodilators for Heart Disease Industry Restraints
3 Vasodilators for Heart Disease Market by Manufacturers
  1. 3.1 Global Vasodilators for Heart Disease Production Value by Manufacturers (2021-2026)
  2. 3.2 Global Vasodilators for Heart Disease Production by Manufacturers (2021-2026)
  3. 3.3 Global Vasodilators for Heart Disease Average Price by Manufacturers (2021-2026)
  4. 3.4 Global Vasodilators for Heart Disease Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vasodilators for Heart Disease Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Vasodilators for Heart Disease Manufacturers, Product Type & Application
  7. 3.7 Global Vasodilators for Heart Disease Manufacturers Established Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vasodilators for Heart Disease Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vasodilators for Heart Disease Players Market Share by Production Value in 2025
  11. 3.8.3 2025 Vasodilators for Heart Disease Tier 1, Tier 2, and Tier 3
4 Vasodilators for Heart Disease Market by Type
  1. 4.1 Vasodilators for Heart Disease Type Introduction
  2. 4.1.1 Isosorbide Mononitrate
  3. 4.1.2 Nicorandil
  4. 4.1.3 Nitroglycerin
  5. 4.1.4 Isosorbide Dinitrate
  6. 4.2 Global Vasodilators for Heart Disease Production by Type
  7. 4.2.1 Global Vasodilators for Heart Disease Production by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Vasodilators for Heart Disease Production by Type (2021-2032)
  9. 4.2.3 Global Vasodilators for Heart Disease Production Market Share by Type (2021-2032)
  10. 4.3 Global Vasodilators for Heart Disease Production Value by Type
  11. 4.3.1 Global Vasodilators for Heart Disease Production Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Vasodilators for Heart Disease Production Value by Type (2021-2032)
  13. 4.3.3 Global Vasodilators for Heart Disease Production Value Market Share by Type (2021-2032)
5 Vasodilators for Heart Disease Market by Application
  1. 5.1 Vasodilators for Heart Disease Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Other
  5. 5.2 Global Vasodilators for Heart Disease Production by Application
  6. 5.2.1 Global Vasodilators for Heart Disease Production by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Vasodilators for Heart Disease Production by Application (2021-2032)
  8. 5.2.3 Global Vasodilators for Heart Disease Production Market Share by Application (2021-2032)
  9. 5.3 Global Vasodilators for Heart Disease Production Value by Application
  10. 5.3.1 Global Vasodilators for Heart Disease Production Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Vasodilators for Heart Disease Production Value by Application (2021-2032)
  12. 5.3.3 Global Vasodilators for Heart Disease Production Value Market Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Chongqing Yaoyou Pharmaceutical Co., Ltd.
  2. 6.1.1 Chongqing Yaoyou Pharmaceutical Co., Ltd. Company Information
  3. 6.1.2 Chongqing Yaoyou Pharmaceutical Co., Ltd. Business Overview
  4. 6.1.3 Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  5. 6.1.4 Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  6. 6.1.5 Chongqing Yaoyou Pharmaceutical Co., Ltd. Recent Developments
  7. 6.2 Southwest Pharmaceutical Co., Ltd.
  8. 6.2.1 Southwest Pharmaceutical Co., Ltd. Company Information
  9. 6.2.2 Southwest Pharmaceutical Co., Ltd. Business Overview
  10. 6.2.3 Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  11. 6.2.4 Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  12. 6.2.5 Southwest Pharmaceutical Co., Ltd. Recent Developments
  13. 6.3 Shanghai Hefeng Pharmaceutical Co., Ltd.
  14. 6.3.1 Shanghai Hefeng Pharmaceutical Co., Ltd. Company Information
  15. 6.3.2 Shanghai Hefeng Pharmaceutical Co., Ltd. Business Overview
  16. 6.3.3 Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  17. 6.3.4 Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  18. 6.3.5 Shanghai Hefeng Pharmaceutical Co., Ltd. Recent Developments
  19. 6.4 Shanghai Aifa Pharmaceutical Co., Ltd.
  20. 6.4.1 Shanghai Aifa Pharmaceutical Co., Ltd. Company Information
  21. 6.4.2 Shanghai Aifa Pharmaceutical Co., Ltd. Business Overview
  22. 6.4.3 Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  23. 6.4.4 Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  24. 6.4.5 Shanghai Aifa Pharmaceutical Co., Ltd. Recent Developments
  25. 6.5 Shanxi Kangbao Biological Products Co., Ltd.
  26. 6.5.1 Shanxi Kangbao Biological Products Co., Ltd. Company Information
  27. 6.5.2 Shanxi Kangbao Biological Products Co., Ltd. Business Overview
  28. 6.5.3 Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  29. 6.5.4 Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  30. 6.5.5 Shanxi Kangbao Biological Products Co., Ltd. Recent Developments
  31. 6.6 Shandong New Era Pharmaceutical Co., Ltd.
  32. 6.6.1 Shandong New Era Pharmaceutical Co., Ltd. Company Information
  33. 6.6.2 Shandong New Era Pharmaceutical Co., Ltd. Business Overview
  34. 6.6.3 Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  35. 6.6.4 Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  36. 6.6.5 Shandong New Era Pharmaceutical Co., Ltd. Recent Developments
  37. 6.7 Shandong Fangming Pharmaceutical Group Co., Ltd.
  38. 6.7.1 Shandong Fangming Pharmaceutical Group Co., Ltd. Company Information
  39. 6.7.2 Shandong Fangming Pharmaceutical Group Co., Ltd. Business Overview
  40. 6.7.3 Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  41. 6.7.4 Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  42. 6.7.5 Shandong Fangming Pharmaceutical Group Co., Ltd. Recent Developments
  43. 6.8 Sancai Shiqi Pharmaceutical Co., Ltd.
  44. 6.8.1 Sancai Shiqi Pharmaceutical Co., Ltd. Company Information
  45. 6.8.2 Sancai Shiqi Pharmaceutical Co., Ltd. Business Overview
  46. 6.8.3 Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  47. 6.8.4 Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  48. 6.8.5 Sancai Shiqi Pharmaceutical Co., Ltd. Recent Developments
  49. 6.9 Lunan Beite Pharmaceutical Co., Ltd.
  50. 6.9.1 Lunan Beite Pharmaceutical Co., Ltd. Company Information
  51. 6.9.2 Lunan Beite Pharmaceutical Co., Ltd. Business Overview
  52. 6.9.3 Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  53. 6.9.4 Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  54. 6.9.5 Lunan Beite Pharmaceutical Co., Ltd. Recent Developments
  55. 6.10 Jiangxi Haiersi Pharmaceutical Co., Ltd.
  56. 6.10.1 Jiangxi Haiersi Pharmaceutical Co., Ltd. Company Information
  57. 6.10.2 Jiangxi Haiersi Pharmaceutical Co., Ltd. Business Overview
  58. 6.10.3 Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  59. 6.10.4 Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  60. 6.10.5 Jiangxi Haiersi Pharmaceutical Co., Ltd. Recent Developments
  61. 6.11 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  62. 6.11.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information
  63. 6.11.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview
  64. 6.11.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  65. 6.11.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  66. 6.11.5 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Developments
  67. 6.12 Jiangsu Shenlong Pharmaceutical Co., Ltd.
  68. 6.12.1 Jiangsu Shenlong Pharmaceutical Co., Ltd. Company Information
  69. 6.12.2 Jiangsu Shenlong Pharmaceutical Co., Ltd. Business Overview
  70. 6.12.3 Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  71. 6.12.4 Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  72. 6.12.5 Jiangsu Shenlong Pharmaceutical Co., Ltd. Recent Developments
  73. 6.13 Jiangsu Jiuxu Pharmaceutical Co., Ltd.
  74. 6.13.1 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Company Information
  75. 6.13.2 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Business Overview
  76. 6.13.3 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  77. 6.13.4 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  78. 6.13.5 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Recent Developments
  79. 6.14 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd.
  80. 6.14.1 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Company Information
  81. 6.14.2 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Business Overview
  82. 6.14.3 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  83. 6.14.4 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  84. 6.14.5 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Recent Developments
  85. 6.15 Hulunbeier Songlu Pharmaceutical Co., Ltd.
  86. 6.15.1 Hulunbeier Songlu Pharmaceutical Co., Ltd. Company Information
  87. 6.15.2 Hulunbeier Songlu Pharmaceutical Co., Ltd. Business Overview
  88. 6.15.3 Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  89. 6.15.4 Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  90. 6.15.5 Hulunbeier Songlu Pharmaceutical Co., Ltd. Recent Developments
  91. 6.16 Henan Runhong Pharmaceutical Co., Ltd.
  92. 6.16.1 Henan Runhong Pharmaceutical Co., Ltd. Company Information
  93. 6.16.2 Henan Runhong Pharmaceutical Co., Ltd. Business Overview
  94. 6.16.3 Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  95. 6.16.4 Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  96. 6.16.5 Henan Runhong Pharmaceutical Co., Ltd. Recent Developments
  97. 6.17 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.
  98. 6.17.1 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Company Information
  99. 6.17.2 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Business Overview
  100. 6.17.3 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  101. 6.17.4 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  102. 6.17.5 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Recent Developments
  103. 6.18 Chenxin Pharmaceutical Co., Ltd.
  104. 6.18.1 Chenxin Pharmaceutical Co., Ltd. Company Information
  105. 6.18.2 Chenxin Pharmaceutical Co., Ltd. Business Overview
  106. 6.18.3 Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  107. 6.18.4 Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  108. 6.18.5 Chenxin Pharmaceutical Co., Ltd. Recent Developments
  109. 6.19 Beijing Yimin Pharmaceutical Co., Ltd.
  110. 6.19.1 Beijing Yimin Pharmaceutical Co., Ltd. Company Information
  111. 6.19.2 Beijing Yimin Pharmaceutical Co., Ltd. Business Overview
  112. 6.19.3 Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  113. 6.19.4 Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  114. 6.19.5 Beijing Yimin Pharmaceutical Co., Ltd. Recent Developments
  115. 6.20 Beijing Hengsheng Pharmaceutical Co., Ltd.
  116. 6.20.1 Beijing Hengsheng Pharmaceutical Co., Ltd. Company Information
  117. 6.20.2 Beijing Hengsheng Pharmaceutical Co., Ltd. Business Overview
  118. 6.20.3 Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  119. 6.20.4 Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  120. 6.20.5 Beijing Hengsheng Pharmaceutical Co., Ltd. Recent Developments
  121. 6.21 Anhui Fengyuan Pharmaceutical Co., Ltd.
  122. 6.21.1 Anhui Fengyuan Pharmaceutical Co., Ltd. Company Information
  123. 6.21.2 Anhui Fengyuan Pharmaceutical Co., Ltd. Business Overview
  124. 6.21.3 Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  125. 6.21.4 Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  126. 6.21.5 Anhui Fengyuan Pharmaceutical Co., Ltd. Recent Developments
  127. 6.22 TORRENT PHARMA INC.
  128. 6.22.1 TORRENT PHARMA INC. Company Information
  129. 6.22.2 TORRENT PHARMA INC. Business Overview
  130. 6.22.3 TORRENT PHARMA INC. Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  131. 6.22.4 TORRENT PHARMA INC. Vasodilators for Heart Disease Product Portfolio
  132. 6.22.5 TORRENT PHARMA INC. Recent Developments
  133. 6.23 Sanofi
  134. 6.23.1 Sanofi Company Information
  135. 6.23.2 Sanofi Business Overview
  136. 6.23.3 Sanofi Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  137. 6.23.4 Sanofi Vasodilators for Heart Disease Product Portfolio
  138. 6.23.5 Sanofi Recent Developments
  139. 6.24 Pfizer
  140. 6.24.1 Pfizer Company Information
  141. 6.24.2 Pfizer Business Overview
  142. 6.24.3 Pfizer Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  143. 6.24.4 Pfizer Vasodilators for Heart Disease Product Portfolio
  144. 6.24.5 Pfizer Recent Developments
  145. 6.25 Matins Pharma
  146. 6.25.1 Matins Pharma Company Information
  147. 6.25.2 Matins Pharma Business Overview
  148. 6.25.3 Matins Pharma Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  149. 6.25.4 Matins Pharma Vasodilators for Heart Disease Product Portfolio
  150. 6.25.5 Matins Pharma Recent Developments
  151. 6.26 Copperhead Chemical Company
  152. 6.26.1 Copperhead Chemical Company Company Information
  153. 6.26.2 Copperhead Chemical Company Business Overview
  154. 6.26.3 Copperhead Chemical Company Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  155. 6.26.4 Copperhead Chemical Company Vasodilators for Heart Disease Product Portfolio
  156. 6.26.5 Copperhead Chemical Company Recent Developments
  157. 6.27 Axplora
  158. 6.27.1 Axplora Company Information
  159. 6.27.2 Axplora Business Overview
  160. 6.27.3 Axplora Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  161. 6.27.4 Axplora Vasodilators for Heart Disease Product Portfolio
  162. 6.27.5 Axplora Recent Developments
  163. 6.28 Aditya Chemicals
  164. 6.28.1 Aditya Chemicals Company Information
  165. 6.28.2 Aditya Chemicals Business Overview
  166. 6.28.3 Aditya Chemicals Vasodilators for Heart Disease Production, Value and Gross Margin (2021-2026)
  167. 6.28.4 Aditya Chemicals Vasodilators for Heart Disease Product Portfolio
  168. 6.28.5 Aditya Chemicals Recent Developments
7 Global Vasodilators for Heart Disease Production by Region
  1. 7.1 Global Vasodilators for Heart Disease Production by Region: 2021 VS 2025 VS 2032
  2. 7.2 Global Vasodilators for Heart Disease Production by Region (2021-2032)
  3. 7.2.1 Global Vasodilators for Heart Disease Production by Region (2021-2026)
  4. 7.2.2 Global Vasodilators for Heart Disease Production Forecast by Region (2027-2032)
  5. 7.3 Global Vasodilators for Heart Disease Production by Region: 2021 VS 2025 VS 2032
  6. 7.4 Global Vasodilators for Heart Disease Production Value by Region (2021-2032)
  7. 7.4.1 Global Vasodilators for Heart Disease Production Value by Region (2021-2026)
  8. 7.4.2 Global Vasodilators for Heart Disease Production Value by Region (2027-2032)
  9. 7.5 Global Vasodilators for Heart Disease Market Price Analysis by Region (2021-2032)
  10. 7.6 Regional Production Value Trends (2021-2032)
  11. 7.6.1 North America Vasodilators for Heart Disease Production Value (2021-2032)
  12. 7.6.2 Europe Vasodilators for Heart Disease Production Value (2021-2032)
  13. 7.6.3 Asia-Pacific Vasodilators for Heart Disease Production Value (2021-2032)
  14. 7.6.4 South America Vasodilators for Heart Disease Production Value (2021-2032)
  15. 7.6.5 Middle East & Africa Vasodilators for Heart Disease Production Value (2021-2032)
8 Global Vasodilators for Heart Disease Consumption by Region
  1. 8.1 Global Vasodilators for Heart Disease Consumption by Region: 2021 VS 2025 VS 2032
  2. 8.2 Global Vasodilators for Heart Disease Consumption by Region (2021-2032)
  3. 8.2.1 Global Vasodilators for Heart Disease Consumption by Region (2021-2026)
  4. 8.2.2 Global Vasodilators for Heart Disease Consumption by Region (2027-2032)
  5. 8.3 North America
  6. 8.3.1 North America Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 8.3.2 North America Vasodilators for Heart Disease Consumption by Country (2021-2032)
  8. 8.3.3 U.S.
  9. 8.3.4 Canada
  10. 8.3.5 Mexico
  11. 8.4 Europe
  12. 8.4.1 Europe Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 8.4.2 Europe Vasodilators for Heart Disease Consumption by Country (2021-2032)
  14. 8.4.3 Germany
  15. 8.4.4 France
  16. 8.4.5 U.K.
  17. 8.4.6 Italy
  18. 8.4.7 Netherlands
  19. 8.5 Asia Pacific
  20. 8.5.1 Asia Pacific Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 8.5.2 Asia Pacific Vasodilators for Heart Disease Consumption by Country (2021-2032)
  22. 8.5.3 China
  23. 8.5.4 Japan
  24. 8.5.5 South Korea
  25. 8.5.6 Southeast Asia
  26. 8.5.7 India
  27. 8.5.8 Australia
  28. 8.6 South America
  29. 8.6.1 South America Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 8.6.2 South America Vasodilators for Heart Disease Consumption by Country (2021-2032)
  31. 8.6.3 Brazil
  32. 8.6.4 Argentina
  33. 8.6.5 Chile
  34. 8.6.6 Colombia
  35. 8.7 Middle East & Africa
  36. 8.7.1 Middle East & Africa Vasodilators for Heart Disease Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
  37. 8.7.2 Middle East & Africa Vasodilators for Heart Disease Consumption by Country (2021-2032)
  38. 8.7.3 Egypt
  39. 8.7.4 South Africa
  40. 8.7.5 Israel
  41. 8.7.6 Türkiye
  42. 8.7.7 GCC Countries
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vasodilators for Heart Disease Value Chain Analysis
  2. 9.1.1 Vasodilators for Heart Disease Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vasodilators for Heart Disease Production Mode & Process
  6. 9.2 Vasodilators for Heart Disease Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vasodilators for Heart Disease Distributors
  9. 9.2.3 Vasodilators for Heart Disease Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst